Penicillins Carbapen

Penicillin G

Penicillin VK

Nafcillin

Oxacillin

Cloxacillin

Flucloxacillin

Dicloxacillin

Ampicillin

Amoxicillin

Amox-Clav

Amp-Sulb

Pip-Tazo

Doripenem
Antibacterials

Aerobic gram-pos cocci

E. faecalis (S) ++ 0 0 0 0 0 0 ++ ++ + + + +/-
E. faecium (S) +/- 0 0 0 0 0 0 +/- +/- +/- +/- +/- 0
E. faecalis (VRE) +/- 0 0 0 0 0 0 +/- +/- +/- +/- +/- 0
E. faecium (VRE) +/- 0 0 0 0 0 0 +/- +/- +/- +/- +/- 0
S. aureus MSSA +/- +/- ++ ++ ++ ++ ++ +/- +/- + + + +*
S. aureus HA-MRSA 0 0 0 0 0 0 0 0 0 0 0 0 0
S. aureus CA-MRSA 0 0 0 0 0 0 0 0 0 0 0 0 0
Staph coag-neg (S) +/- +/- ++ ++ ++ ++ ++ +/- +/- + + + +
Staph coag-neg (R) 0 0 0 0 0 0 0 0 0 0 0 0 0
S. epidermidis (R) 0 0 0 0 0 0 0 0 0 0 0 0 0
S. epidermidis (S) +/- +/- ++ ++ ++ ++ ++ +/- +/- + + + +
S. lugdunensis +/- +/- ++ ++ ++ ++ ++ +/- +/- + + + +
S. saprophyticus +/- +/- + + + + + +/- +/- ++ + + +
Strep. anginosis gp ++ ++ + + + + + + + + + + +
Strep. pyogenes (A) ++ ++ + + + + + + + + + + +
Strep. agalactiae (B) ++ ++ + + + + + + + + + + +
Strep. gp C,F,G ++ ++ + + + + + + + + + + +
Strep. pneumoniae ++ ++ + + + + + + + + + + +*
Viridans Strep. +/- +/- +/- +/- +/- +/- +/- +/- +/- +/- +/- +/- +
Aerobic gram-pos bacilli
Arcanobacter. sp + + ? ? ? ? ? + + + + + +
C. diphtheriae ++ ++ 0 0 0 0 0 + + + + + ?
C. jeikeium 0 0 0 0 0 0 0 0 0 0 0 0 0
L. monocytogenes + 0 0 0 0 0 0 ++ + + + + ?
Nocardia sp. 0 0 0 0 0 0 0 0 0 +/- ? ? ?
Aerobic GNB - Enteric
Aeromonas sp. 0 0 0 0 0 0 0 0 0 +/- +/- + +
C. jejuni 0 0 0 0 0 0 0 0 0 + 0 0 +
C. freundii 0 0 0 0 0 0 0 0 0 0 0 ++ +
C. koseri 0 0 0 0 0 0 0 0 0 0 0 ++ +
E. aerogenes 0 0 0 0 0 0 0 0 0 0 0 + +
E. cloacae 0 0 0 0 0 0 0 0 0 0 0 + +
E. coli (S) 0 0 0 0 0 0 0 +/- +/- + + + +*
E. coli, Klebs ESBL 0 0 0 0 0 0 0 0 0 0 0 +/- +*
E. coli, Klebs KPC 0 0 0 0 0 0 0 0 0 0 0 0 0
E. coli, Klebs MBL 0 0 0 0 0 0 0 0 0 0 0 0 0
Enterics CRE, NOS 0 0 0 0 0 0 0 0 0 0 0 0 0
K. oxytoca 0 0 0 0 0 0 0 0 0 + + + +
K. pneumoniae (S) 0 0 0 0 0 0 0 0 0 + + + +*
Morganella sp. 0 0 0 0 0 0 0 0 0 0 0 + +
P. mirabilis 0 0 0 0 0 0 0 + + + + + +
P. vulgaris 0 0 0 0 0 0 0 0 0 + + + +
Providencia sp. 0 0 0 0 0 0 0 0 0 0 0 + ++
Salmonella sp. 0 0 0 0 0 0 0 +/- +/- + + + +
Serratia sp. 0 0 0 0 0 0 0 0 0 0 0 + +
Shigella sp. 0 0 0 0 0 0 0 0 0 + + + +
Y. enterolitica 0 0 0 0 0 0 0 0 0 +/- +/- + +
Aerobic GNB - Non-enteric
Bartonella sp. 0 0 0 0 0 0 0 0 0 0 0 0 0
B. pertussis 0 0 0 0 0 0 0 0 0 0 0 0 0
B. burgdoferi + 0 0 0 0 0 0 ++ ++ + + 0 0
Brucella sp. 0 0 0 0 0 0 0 0 0 0 0 0 0
Capnocytophagia +/- +/- 0 0 0 0 0 +/- +/- ++ + ++ +
C. burnetii 0 0 0 0 0 0 0 0 0 0 0 0 0
Ehrlichia, Anaplas 0 0 0 0 0 0 0 0 0 0 0 0 0
Eikenella sp +/- +/- 0 0 0 0 0 +/- +/- + + + +
F. tularensis 0 0 0 0 0 0 0 0 0 0 0 0 0
H. ducreyi 0 0 0 0 0 0 0 0 0 0 0 0 ?
H. influenzae 0 0 0 0 0 0 0 +/- +/- ++ ++ + +
Kingella sp. + + 0 0 0 0 0 + + + + + +
K. granulomatis 0 0 0 0 0 0 0 0 0 0 0 0 0
Legionella sp. 0 0 0 0 0 0 0 0 0 0 0 0 0
Leptospira sp. ++ 0 0 0 0 0 0 + + + + + +
M. catarrhalis 0 0 0 0 0 0 0 0 0 ++ + + +
N. gonorrhoeae 0 0 0 0 0 0 0 0 0 0 0 0 +
N. meningitidis + 0 0 0 0 0 0 ++ ++ 0 0 + +
P. multocida ++ ++ 0 0 0 0 0 ++ ++ ++ ++ + +
R. ricketsii 0 0 0 0 0 0 0 0 0 0 0 0 0
T. pallidum ++ 0 0 0 0 0 0 0 0 0 0 0 0
V. cholera 0 0 0 0 0 0 0 0 0 0 0 0 0
V. parahemolyticus 0 0 0 0 0 0 0 0 0 0 0 0 ?
V. vulnificus 0 0 0 0 0 0 0 0 0 0 0 0 ?
Y. pestis 0 0 0 0 0 0 0 0 0 0 0 0 0
Aerobic GNB non-fermenter
A. baumanii 0 0 0 0 0 0 0 0 0 0 +/- +/- + *
B. cepacia 0 0 0 0 0 0 0 0 0 0 0 0 +/-
P. aeruginosa 0 0 0 0 0 0 0 0 0 0 0 + +*
S. maltophilia 0 0 0 0 0 0 0 0 0 0 0 +/- 0
Aerobic - cell wall-deficient
C. trachomatis 0 0 0 0 0 0 0 +* +*0 0 0 0
Chlamydophila sp. 0 0 0 0 0 0 0 0 0 0 0 0 0
M. genitalium 0 0 0 0 0 0 0 0 0 0 0 0 0
M. pneumoniae 0 0 0 0 0 0 0 0 0 0 0 0 0
U. urealyticum 0 0 0 0 0 0 0 0 0 0 0 0 0
Anaerobic GNB
B. fragilis 0 0 0 0 0 0 0 0 0 ++ + ++ +
F. necrophorum +/- +/- 0 0 0 0 0 +/- +/- + + + +
P. melaninogenica +/- +/- 0 0 0 0 0 +/- +/- + + + +
Anaerobic gram-positive
Actinomyces sp. ++ ++ 0 0 0 0 0 ++ ++ + + + +
C. difficille 0 0 0 0 0 0 0 0 0 0 0 0 0
Clostridum sp. ++ + 0 0 0 0 0 + + + + + +
P. acnes ++ + ? ? ? ? ? + + + + + +
Peptostreptococci ++ ++ 0 0 0 0 0 ++ ++ + + + +
 Carbapenems Fluoroquinolone Parenteral Cephalosporins
Ertapenem

Imipenem

Meropenem

Mero-Vabor

Aztreonam

Ciprofloxacin

Delafloxacin

Ofloxacin

Levofloxacin

Moxifloxacin

Norfloxacin

Prulifloxacin

Gemifloxacin

Gatifloxacin

Cefazolin

Cefotetan

Cefoxitin

Cefuroxime

Cefotaxime

Ceftizoxime

Ceftriaxone
+/- +/- +/- +/- 0 +/-* + +/- + + + +/-* + + 0 0 0 0 0 0 +/-*
0 0 0 0 0 0 0 0 0 +/- 0 0 +/- +/- 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
+ + + + 0 0 + + + + 0 0 + + ++ + + + + + +
0 0 0 0 0 0 + 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 + +/- +/- +/- 0 0 +/- +/- 0 0 0 0 0 0 0
+ + + + 0 + + + + + 0 + + + ++ + + + + + +
0 0 0 0 0 0 + 0 +/- +/- 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 + 0 +/- +/- 0 0 0 0 0 0 0 0 0 0 0
+ + + + 0 + + + + + 0 + + + ++ + + + + + +
+ + + + 0 0 + + + + 0 0 + + ++ + + + + + +
+ + + + 0 + + + + + 0 + + + ++ + + + + + +
+ + + + 0 +/- + +/- +/- +/- 0 +/- +/- +/- + + + + + + +
+ + + + 0 +/- + +/- +/- +/- 0 +/- +/- +/- + + + + + + +
+ + + + 0 +/- + +/- +/- +/- 0 +/- +/- +/- + + + + + + +
+ + + + 0 +/- + +/- +/- +/- 0 +/- +/- +/- + + + + + + +
+ + + + 0 +/- + +/- + + 0 +/- + + + + + + + + +
+ + + + 0 0 + 0 + + 0 0 + + + + + + ++ + ++

+ + + + 0 + ? + + + 0 + + + + + + + + + +
? ? ? ? 0 ? ? ? ? ? 0 ? ? ? ? ? ? ? ? ? ?
0 0 0 0 0 0 ? 0 0 +/- 0 0 +/- 0 0 0 0 0 0 0 0
? ? +/- +/- 0 0 + 0 + + 0 0 + + 0 0 0 0 0 0 0
0 ++ + + 0 0 ? 0 0 0 0 0 0 0 0 0 0 0 +/- 0 +/-*

+ + + + + + + + + + 0 + + + 0 0 0 ? + + +
+ + + + ? + + + + + 0 + + + 0 0 0 0 + + +
+ + ++ + +/- + + + + + + + + + 0 0 0 0 +/- +/- +/-
+ + ++ + +/- + + + + + + + + + 0 0 0 0 +/- +/- +/-
+ + + + + + + + + + + + + + 0 0 0 0 0 0 0
+ + + + + + + + + + + + + + 0 0 0 0 0 0 0
+ + + + + + + + + + + + + + + + + + + + +
+ ++ ++ + 0 +/- +/- +/- +/- +/- +/- +/- +/- +/- 0 +/- +/- 0 0 0 0
 0 0 0 ++ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 +/-* +/- 0 0 +/- 0 0 +/- 0 0 0 0 0 0 0 0 0
0 0 0 +/- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
+ + + + + + + + + + + + + + + + + + + + +
+ + + + + + + + + + + + + + + + + + + + +
+ +/-* + + + + + + + ? + + ? ? 0 + + 0 + + +
+ +/-* + + + + + + + + + + + + + + + + + + +
+ +/-* + + + + + + + + + + + + 0 + + + + + +
++ +/-* ++ + + + + + + + + + ? ? 0 + + 0 + + +
+ + + + + + + + + + 0 + + + 0 ? ? ? + + +
+ + + + + + + + + + 0 + + + 0 + 0 0 + + +
+ + + + + ++ + + ++ + 0 ++ + + 0 ? ? ? + + +
? + + + + ++ + + ++ + 0 ++ ? + 0 +/- +/- +/-* ++ + ++

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 ? ? ? ? ? 0 ? ? ? 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 + + 0 ++
0 0 0 0 0 + ? ? ? ? 0 + ? ? 0 0 0 0 0 0 0
? ++ ++ + 0 +/- ? +/- +/- ? 0 +/- ? ? 0 0 0 0 + ? +
0 0 0 0 0 + ? + + + 0 + +* +* 0 0 0 0 0 0 0
0 0 0 0 0 ? ? ? ?* ? 0 ? 0 0 0 0 0 0 0 0 0
+ + + + ? + ? + + ? 0 + ? ? 0 ? + 0 + ? +
0 0 0 0 0 ++ ? ? ? ? 0 ++ ? ? 0 0 0 0 0 0 0
? ? ? ? ? ++ ? ? + ? 0 ++ ? ? 0 0 0 0 0 0 ++
+ + + + + + + + ++ ++ 0 + + + 0 + + + ++ + ++
+ + + + ? + + + ++ ? 0 + ? ? + + + + + + ++
0 0 0 0 0 ++ ? ? ? ? 0 ++ ? ? 0 0 + 0 0 0 +
0 0 0 0 0 ++ + ++ ++ ++ 0 ++ + + 0 0 0 0 0 0 0
+ + + + + + + + + + 0 + + + ? ? ? ? ++ ? ++
+ + + + + + + + + + 0 + + + 0 + +/- + + + +
+ + + + + +/- ? +/- +/- 0 0 +/- +* 0 +/- +/- +/- 0 +/- +/- ++
+ + + + + ? ? ? ? ? 0 ? ? ? 0 0 0 + + + ++
+ + + + + + + + + + 0 + + + 0 ? ? + + + +
0 0 0 0 0 +/- ? +/- +/- +/- 0 +/- ? ? 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +
0 0 0 0 0 + ? ? ? ? 0 + ? ? 0 0 0 0 0 0 0
? ? ? ? ? + ? + + ? 0 + ? ? 0 0 0 0 + + +
? ? ? ? ? + ? + + ? 0 + ? ? 0 0 0 0 + + +
0 0 0 0 0 + ? ? ? ? 0 + ? ? 0 0 0 0 0 0 0

0 ++ +/- +/- 0 +/- ? +/- +/- +/- 0 +/- ? ? 0 0 0 0 0 0 +/-

0 0 +/- +/- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 + + + + + + 0 + 0 0 + 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 ? 0 +/- +/- 0 0 ? ? 0 0 0 0 0 0 0

0 0 0 0 0 0 ? ++ ++ + 0 0 + + 0 0 0 0 0 0 0
0 0 0 0 0 + ? + + + 0 + + + 0 0 0 0 0 0 0
0 0 0 0 0 0 ? 0 +/- ++ 0 0 ? +* 0 0 0 0 0 0 0
0 0 0 0 0 + ? + ++ *++ 0 + + + 0 0 0 0 0 0 0
0 0 0 0 0 + ? + + + 0 + ? ? 0 0 0 0 0 0 0

++ ++ ++ + 0 0 + 0 0 +/- 0 0 0 0 0 +/- +/- 0 0 + 0

+ + + + 0 0 ? 0 0 ? 0 0 ? ? 0 + + ? + ? +*
+ + + + 0 0 ? 0 +/- + 0 0 ? ? 0 + + ? ? ? ?

+ + + + 0 0 ? 0 ? ? 0 0 ? ? 0 ? + 0 + + +
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
+ + + + 0 0 + 0 0 0 0 0 0 0 0 + + ? + + +
+ + + + 0 +/- 0 +/- +/- +/- 0 +/- ? ? + + + + + + ++
+ + + + 0 0 + 0 + + 0 0 ? + + + + + + + +
Parenteral Cephalosporins Oral Cephalosporins Aminoglyc Macrolides
o
Ceftazidime

Cefepime

Ceftaz-Avibac

Ceftaroline

Ceftol-Tazo

Cefadroxil

Cephalexin

Cefaclor

Cefprozil

Cefurox-Axe

Cefixime

Ceftibuten

Cefpodoxime

Cefdinir

Cefditoren

Gentamicin

Tobramycin

Amikacin

l
Chloramphenico
Clindamycin

Erythromycin
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +/-* 0 0 +/- 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +/-* 0 0 +/- 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +/-* 0 0 +/- 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +/-* 0 NA +/- 0 0
+/- + +/- + ? + + + + + 0 0 + + + +/-* ? ? + + +/-
0 0 0 + 0 0 0 0 0 0 0 0 0 0 0 +/-* ? ? + +/- 0
0 0 0 + 0 0 0 0 0 0 0 0 0 0 0 +/-* ? ? + + 0
+/- + +/- + ? +/- +/- +/- + + 0 0 + + + +/-* ? ? + + +/-
0 0 0 + 0 0 0 0 0 0 0 0 0 0 0 +/-* ? ? + +/- 0
0 0 0 + 0 0 0 0 0 0 0 0 0 0 0 +/-* ? ? + +/- 0
+/- + +/- + ? + + + + + ? ? + + + +/-* ? ? + + +
+/- + +/- + ? + + + + + ? ? + + + +/-* ? ? + + +
+/- + +/- + ? ++ ++ ++ + + ? ? + + + 0 0 0 + + +/-
+ + + + + + + + + + + + + + + +/-* ? ? + + +/-
+ + + + + + + + + + + + + + + +/- 0 0 + + +/-
+ + + + + + + + + + + + + + + +/- 0 0 + + +/-
+ + + + + + + + + + + + + + + +/-* 0 0 + + +/-
+ + + + + + + + + + + + + + + 0 0 0 + + +/-
+/- + +/- + + + + + 0 + + 0 + + + +/-* 0 0 + +/- +/-

+ + + + ? + + + + + + + + + ? ? ? ? ? ++ ++
? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 0 0 0 0 + ++
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +/-* ? ? 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ++ 0 0 0
*

+ + + ? ? ? 0 ? ? ? ? ? ? ? ? + + + + 0 0
+ + + ? ? 0 0 0 0 0 0 0 0 0 0 + + + ? ? ++
+/- ++ + + + 0 0 0 0 0 + + + + ? + + + ? 0 0
+/- ++ + + + 0 0 0 0 0 + + + + ? + + + ? 0 0
0 + + 0 + 0 0 0 0 0 0 0 0 0 0 + + + 0 0 0
0 + + 0 + 0 0 0 0 0 0 0 0 0 0 + + + 0 0 0
+ + + + + +/- +/- +/- + + + + + + ? + + + + 0 0
0 0 + 0 + 0 0 0 0 0 0 0 0 0 0 +/- +/- +/- +/- 0 0
 0 0 ++ 0 0 0 0 0 0 0 0 0 0 0 0 +/- +/- +/- 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +/- +/- +/- 0 0 0
0 0 +/- 0 0 0 0 0 0 0 0 0 0 0 0 +/- +/- +/- 0 0 0
+ + + + + +/- +/- +/- + + + + + + ? + + + + 0 0
+ + + + + +/- +/- +/- + + + + + + ? + + + + 0 0
+ ++ + + + 0 0 0 0 0 0 0 0 0 0 + + + ? 0 0
+ + + + + + + + + + + + + + ? + + + ? 0 0
+ + + ? + 0 0 0 0 0 + + + ? ? + + + +/- 0 0
+ + + ? + 0 0 0 0 0 + + + ? ? +/- +/- + ? 0 0
+ + + ? ? 0 0 0 0 0 + + + + ? + + + + 0 0
+ + + ? + 0 0 0 0 0 + 0 0 0 0 + + + 0 0 0
+ + + ? ? 0 0 0 0 0 + + + + ? + + + + 0 0
+/-* ++ ? ? ? 0 0 0 0 0 + + ? ? ? + + + 0 0 0

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ++ 0 0 0 0 +
*
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +
0 0 0 0 0 0 0 0 0 ++ 0 0 0 0 0 0 0 0 0 0 +
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 + ? ? + 0 0
+ + + 0 0 0 0 0 0 0 0 0 0 0 0 +/- +/- +/- + ++ ?
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 + 0 +
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +/- 0 0
? ? ? ? ? 0 0 0 ? 0 ? ? ? ? ? +/- 0 0 + 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ++ + ? + ? 0
0 ? 0 0 0 0 0 0 0 0 0 0 0 0 0 *
0 0 0 0 0 ++
+ + + + + 0 0 +/- + + + + + + + 0 0 0 + 0 0
+ + + + + 0 0 0 + 0 + + + + + + 0 0 + 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 + ? ? + 0 ++
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ++
? + + ? ? ? ? ? ? ? ? ? ? ? ? 0 0 0 + 0 +
+ + + + + 0 0 +/- + + + + + + + 0 0 0 0 0 +
? + ? ? ? 0 0 0 0 0 + 0 + 0 0 0 0 0 0 0 0
+ + + ? ? 0 0 0 0 0 0 0 0 0 0 0 0 0 + 0 0
? + ? + + ? 0 0 ? + + ? + + ? +/- +/- +/- ? 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 + 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +
+ + + ? ? 0 0 0 0 0 0 0 0 0 0 ? ? ? + ? ?
+ + + ? ? 0 0 0 0 0 0 0 0 0 0 ? ? ? + 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 + ? ? + 0 0

+/- +/- ? ? +/- 0 0 0 0 0 0 0 0 0 0 0 0 +/- 0 0 0

+/- +/- + 0 + 0 0 0 0 0 0 +/- 0 0 0 0 0 0 +/- 0 0
+ + + 0 + 0 0 0 0 0 0 0 0 0 0 + + + 0 0 0
+/- 0 +/- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 + 0 0

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 + 0 +
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ?
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +/-
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ++

0 0 0 0 + 0 0 0 0 0 0 0 0 0 0 0 0 0 + +/- 0
? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 0 0 0 + + 0
? ? ? ? + ? ? ? ? ? ? ? ? ? ? 0 0 0 + + +/-

? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 0 0 0 + ++ ++
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 0 0 0 + + +
+ + + + + + 0 + + + + + ? ? ? + ? ? + +/- +/-
+ + + + + + + + + + + + + ? ? 0 0 0 + + +/-
 Macrolides Tetracycline Glyco/Lipo Ox-lid Poly Other
s
Azithromycin

Clarithromycin

Telithromycin

Doxycycline

Minocycline

Tetracycline

Tigecycline

Daptomycin

Vancomycin

Teicoplanin

Telavancin

Oritavancin

Dalbavancin

Linezolid

Tedizolid

Polymyxin B

Colistin

Fusidic Acid

Rif (comb)

TMP-SMX

Nitrofurantoin
0 0 0 +/- +/- +/- + + ++ ++ + + + + +0 0 +/- +/-* 0 +
0 0 0 +/- +/- +/- + + +/- +/- +/- + +/- ++ +0 0 +/- +/-* 0 +
0 0 0 +/- +/- +/- +/- + 0 0 +/- + 0 ++ +0 0 0 +/-* 0 +
0 0 0 +/- +/- +/- +/- + 0 0 +/- + 0 ++ +0 0 0 +/-* 0 +
+/- +/- + + + + + + + + + + + + +0 0 + +/-* + 0
0 0 +/- + + +/- + ++ ++ ++ + + + ++ +0 0 + +/-* + 0
0 0 +/- + + +/- * ++ ++ + +
+ ++ + + +0 0 + +/-* + 0
+/- +/- + + + + + +* + + + + + + +0 0 + +/-* + 0
0 0 +/- +/- +/- +/- + ++ ++ ++ + + + ++ +0 0 + +/-* + 0
0 0 +/- +/- +/- +/- + ++ ++ ++ + + + ++ +0 0 + +/- + 0
+ + + + + + + + + + + + + + +0 0 + +/- + 0
+ + + + + + + + + + + + + + +0 0 + +/-* + 0
+/- +/- ? + + + + + + + + ? ? 0 0 0 0 0 0 + +
+/- +/- + +/- +/- +/- +0* + + + + + + +0 0 ? 0 0 0
+/- +/- + ? ? ? + + + + + + + + +0 0 ? 0 +/- 0
+/- +/- + ? ? ? + + + + + + + + +0 0 ? 0 +/- 0
+/- +/- + ? ? ? + + + + + + + + +0 0 ? 0 +/- 0
+/- +/- + +/- +/- +/- + +/- + + + ? ? + +0 0 ? 0 +/- 0
+/- +/- + +/- +/- +/- + 0 * ++ ++ + + + + +0 0 ? 0 ? 0

++ ++ + ++ + + + + ++ + + ? ? + ?0 0 0 0 0 0
+ + ? ? ? ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 ? ? ? + * + ++ + + 0 0 + ?0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 + ?0 0 0 0 + 0
? ? ? ? +/- 0 ? 0 0 0 0 0 0 + ?0 0 0 0 ++ 0

0 0 0 + + 0 + 0 0 0 0 0 0 0 0+ + 0 0 + 0
++ + 0 +/- +/- +/- ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 +* 0 0 0 0 0 0 0 0+ + 0 0 +/- +/-
0 0 0 0 0 0 +* 0 0 0 0 0 0 0 0+ + 0 0 +/- +/-
0 0 0 0 0 0 +* 0 0 0 0 0 0 0 0+ + 0 0 + +/-
0 0 0 0 0 0 +* 0 0 0 0 0 0 0 0+ + 0 0 + +/-
+/-* 0 0 +/- +/- +/- + * 0 0 0 0 0 0 0 0+ + 0 0 +/- +
0 0 0 0 0 0 +* 0 0 0 0 0 0 0 0+ + 0 0 +/- +/-
0 0 0 0 0 0 +* 0 0 0 0 0 0 0 0+ + 0 0 +/- +/-
0 0 0 0 0 0 + 0 0 0 0 0 0 0 0+ + 0 0 0 0
0 0 0 0 0 0 +* 0 0 0 0 0 0 0 0+ + 0 0 +/- +/-
0 0 0 0 +/- 0 + 0 0 0 0 0 0 0 0+ + 0 0 +/- +
0 0 0 0 +/- 0 +* 0 0 0 0 0 0 0 0+ + 0 0 +/- +
0 0 0 0 0 0 ?* 0 0 0 0 0 0 0 0 0 0 0 0 +/- 0
0 0 0 0 +/- 0 + 0 0 0 0 0 0 0 0 0 0 0 0 +/- 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +/- 0
0 0 0 0 0 0 ? 0 0 0 0 0 0 0 0 0 0 0 0 +/- 0
+ 0 0 +/- +/- 0 +* 0 0 0 0 0 0 0 0 0 0 0 0 +/- 0
0 0 0 0 0 0 +* 0 0 0 0 0 0 0 0 0 0 0 0 + 0
+ 0 0 +/- +/- 0 +* 0 0 0 0 0 0 0 0 0 0 0 0 +/- 0
0 0 0 + ? ? ? 0 0 0 0 0 0 0 0 0 0 0 0 + 0

++ ++ ? ++ + + ? 0 0 0 0 0 0 0 0 0 0 0 +/-* 0 0
++ ++ ? ? ? ? 0 0 0 0 0 0 0 0 0 0 0 0 0 + 0
+ + ? ++ + + ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 + + + ? 0 0 0 0 0 0 0 0 0 0 0 +/-* + 0
? ? ? + + + ? 0 0 0 0 0 0 0 0 0 0 0 0 +/- 0
+ + ? ++ + + ? 0 0 0 0 0 0 0 0 0 0 0 +/-* + 0
0 0 0 ++ + + ? 0 0 0 0 0 0 0 0 0 0 0 +/-* 0 0
0 0 0 + + + ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0
? ? ? ++ + + ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0
++ ? ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
+ + + + + + + 0 0 0 0 0 0 0 0 0 0 0 0 + 0
? ? ? + + + + 0 0 0 0 0 0 0 0 0 0 0 0 + 0
++ + 0 ++ + + ? 0 0 0 0 0 0 0 0 0 0 0 0 ++ 0
++ ++ + + + + + 0 0 0 0 0 0 0 0 0 0 0 +/-* + 0
++ + ? ++ + + ? 0 0 0 0 0 0 0 0 0 0 0 0 ? 0
+ + + + + + ? 0 0 0 0 0 0 0 0 0 0 0 0 + 0
+ 0 0 +/- +/- +/- ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
+ 0 0 + + + + 0 0 0 0 0 0 0 0 0 0 0 0 + 0
0 +/- 0 ++ + + ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0
+ 0 0 + ? +* ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0
+ ? ? + + + ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0
+ 0 0 + ? +* ? 0 0 0 0 0 0 0 0 0 0 0 0 ? 0
? 0 0 + + +* ? 0 0 0 0 0 0 0 0 0 0 0 0 ? 0
0 0 0 + + + ? 0 0 0 0 0 0 0 0 0 0 0 0 + 0

0 0 0 0 +/- +/- + * 0 0 0 0 0 0 0 0+ + 0 0 +/- 0

0 0 0 0 +/- +/- 0 0 0 0 0 0 0 0 0 0 0 0 0 +/- 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0+ + 0 0 0 0
0 0 0 + + 0 +* 0 0 0 0 0 0 0 0+ + 0 0 ++ 0

++ + ? ++ + + 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
+ + + ++ + + + 0 0 0 0 0 0 0 0 0 0 0 +/-* 0 0
++ ? ? +/- +/- +/- ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0
* +/- +/- ++ ++ ++
+/- + 0 0 0 0 0 0 0 0 0 0 0 0 0 0
++ + ? ++ + + ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0
*

0 0 0 +/- +/- +/- + 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 + + + + 0 0 0 0 0 0 0 0 0 0 0 0 0 0
+/- +/- 0 + + + + 0 0 0 0 0 0 0 0 0 0 0 0 0 0

+ + ? + + + ? 0 ? 0 ? 0 0 + ?0 0 0 0 0 0
0 0 0 0 0 0 0 0 ++ 0 0 0 0 0 0 0 0 0 0 0 0
+ + ? + + + + +/- + + + + + + 0 0 0 0 0 0 0
+/- +/- ? + + + + + + + + + + 0 0 0 0 0 0 +/- 0
+/- +/- ? + + + + + + + + + + + ?0 0 0 0 0 0
Other
Fosfomycin (IV)

Fosfomycin (po)

Metronidazole

Quinu-Dalfo

Fluconazole

Itraconazole

Voriconazole

Posaconazole

Isavuconazole

Anidulafungin

Caspofungin

Micafungin

Amphotericin B
Antifungal Drugs

Fungi
+/- +/- 0 0 Aspergilllus fumigatus 0 +/- ++ + ++ +/- +/- +/- +
+/- +/- 0 + Aspergillus terreus 0 +/- ++ + ++ +/- +/- +/- 0
+/- +/- 0 0 Aspergiullus flavus 0 +/- ++ + ++ +/- +/- +/- +
+/- +/- 0 + Candida albicans ++ + + + + ++ ++ ++ +
+ 0 0 + Candida dubliniensis ++ + + + + ++ ++ ++ ++
+ 0 0 + Candida glabrata +/- +/- +/- +/- +/- ++ ++ ++ ++
+ 0 0 + Candida guilliermondii ++ ++ ++ ++ + ++ ++ ++ ++
+ 0 0 + Candida krusei 0 0 + + + ++ ++ ++ ++
+/- 0 0 + Candida lusitaniae ++ + + + + ++ ++ ++ 0
+/- 0 0 + Candida parapsilosis ++ + + + + + + + ++
+ 0 0 + Candida tropicalis ++ + + + + ++ ++ ++ ++
0 0 0 + Cryptococcus sp. ++ + + + + 0 0 0 ++
+/- +/- 0 0 Dematiaceous molds 0 ++ ++ + + +/- +/- +/- +
0 0 0 + Fusarium sp. 0 +/- +/- +/- +/- 0 0 0 +/-
+ 0 0 + Mucormycosis 0 0 0 + + 0 0 0 ++
+ 0 0 + Scedo apiospermum 0 0 + +/- +/- 0 0 0 0
+ 0 0 + Lomentospora prolificans 0 0 0 0 0 0 0 0 0
+ 0 0 + Trichosporon spp. +/- + + + + 0 0 0 +
0 0 0 + Dimorphic Fungi
Blastomyces +/- ++ + + + 0 0 0 ++
0 0 0 + Coccidioides ++ ++ + + + 0 0 0 ++
0 0 0 0 Histoplasma +/- ++ + + + 0 0 0 ++
0 0 0 ? Sporothrix +/- ++ + + + 0 0 0 ++
0 0 0 0
0 0 0 0 Antibacterials Notes:
• Amikacin, Nocardia sp., Use in combination
• Amoxicillin, C. trachomatis, Recommended only as alternate for pregnant women, due to
concern that bacteria persist rather than being killed.
? 0 0 0 • Ampicillin, C. trachomatis, Recommended only as alternate for pregnant women, due to
concern that bacteria persist rather than being killed.
0 0 0 0 • Azithromycin, E. coli (S), Enterohemorrhagic E.coli are susceptible
• Azithromycin, M. genitalium, resistance reported and emerging to all antibiotics including
+ + 0 0 fluoroquinolones
• Azithromycin, U. urealyticum, Link with STI unclear. Some data suggests in patients with
+ + 0 0 symptoms longer than 3 weeks, 6 days 500mg qd more efficacious than 1g single dose.
• Aztreonam, E. coli, Klebs MBL, Aztreonam is not hydrolyzed by MBLs, but MBL+ strains often
+/- +/- 0 0 have other enzymes that can.
• Ceftazidime, Y. enterolitica, Clinical failures reported
+/- +/- 0 0 • Ceftriaxone, E. faecalis (S) , Use only in combination with ampicillin.
• Ceftriaxone, F. necrophorum, Use in combination with metronidazole
+ + 0 0 • Ceftriaxone, Nocardia sp., May be used as part of combination therapy; never used as
monotherapy
+ + 0 0 • Cefuroxime, Y. enterolitica, Clinical failures reported
• Ciprofloxacin, E. faecalis (S) , Most strains +/-, can be used in UTI, not in systemic infection.
• Daptomycin, S. aureus CA-MRSA, Do not use for pneumonia
• Daptomycin, S. aureus HA-MRSA, Do not use for pneumonia
• Daptomycin, Strep. anginosis gp, Despite in vitro susceptibility, resistance to daptomcyin
emerges rapidly in viridans group streptococci
• Daptomycin, Viridans Strep., Despite in vitro susceptibility, resistance to daptomcyin emerges
rapidly in viridans group streptococci
 have other enzymes that can.
• Ceftazidime, Y. enterolitica, Clinical failures reported
• Ceftriaxone, E. faecalis (S) , Use only in combination with ampicillin.
• Ceftriaxone, F. necrophorum, Use in combination with metronidazole
• Ceftriaxone, Nocardia sp., May be used as part of combination therapy; never used as
monotherapy
• Cefuroxime, Y. enterolitica, Clinical failures reported
• Ciprofloxacin, E. faecalis (S) , Most strains +/-, can be used in UTI, not in systemic infection.
+/- +/- 0 0 • Daptomycin, S. aureus CA-MRSA, Do not use for pneumonia
• Daptomycin, S. aureus HA-MRSA, Do not use for pneumonia
+/- +/- 0 0 • Daptomycin, Strep. anginosis gp, Despite in vitro susceptibility, resistance to daptomcyin
emerges rapidly in viridans group streptococci
+/- +/- 0 0 • Daptomycin, Viridans Strep., Despite in vitro susceptibility, resistance to daptomcyin emerges
+/- +/- 0 0 rapidly in viridans group streptococci
• Doripenem, A. baumanii, Do not use Doripenem to treat any kind of pneumonia
+/- +/- 0 0 •
•
Doripenem, E. coli (S), Do not use Doripenem to treat any kind of pneumonia
Doripenem, E. coli, Klebs ESBL, Do not use Doripenem to treat any kind of pneumonia
0 0 0 0 • Doripenem, K. pneumoniae (S), Do not use Doripenem to treat any kind of pneumonia
• Doripenem, P. aeruginosa, Do not use Doripenem to treat any kind of pneumonia
+ + 0 0 • Doripenem, S. aureus MSSA, Do not use Doripenem to treat any kind of pneumonia.
• Doripenem, Strep. pneumoniae, Do not use Doripenem to treat any kind of pneumonia.
+/- +/- 0 0 • Gatifloxacin, C. burnetii, FQs potential alternative if CNS infected as FQs have good CNS
penetration
+ + 0 0 • Gatifloxacin, M. genitalium, resistance reported and emerging to all antibiotics including
fluoroquinolones
0 0 0 0 • Gemifloxacin, C. burnetii, FQs alternative if CNS infected.
• Gemifloxacin, N. gonorrhoeae, Used in combination with azithro for ceftriaxone resistant
+/- +/- 0 0 strains
• Gentamicin, Bartonella sp., In combination with doxycycline or azithromycin
0 0 0 0 • Gentamicin, E. faecalis (S), Use only in combination.
• Gentamicin, E. faecalis (VRE), Use only in combination
0 0 0 0 • Gentamicin, E. faecium (S), Use only in combination.
• Gentamicin, E. faecium (VRE), Use only in combination
• Gentamicin, F. tularensis, Streptomycin is drug of choice
• Gentamicin, L. monocytogenes, Use only in combination
0 0 0 0 • Gentamicin, S. aureus CA-MRSA, Use only in combination
• Gentamicin, S. aureus HA-MRSA, Use only in combination
0 0 0 0 • Gentamicin, S. aureus MSSA, Use only in combination
0 0 0 0 •
•
Gentamicin, S. epidermidis (R), Use only in combination
Gentamicin, S. epidermidis (S), Use only in combination
0 0 0 0 • Gentamicin, S. lugdunensis, Use only in combination
• Gentamicin, Staph coag-neg (R), Use only in combination
0 0 0 0 • Gentamicin, Staph coag-neg (S), Use only in combination
• Gentamicin, Strep. anginosis gp, Use only in combination
0 0 0 0 • Gentamicin, Strep. gp C,F,G, Use only in combination for Group B strep
• Gentamicin, Viridans Strep., Use only in combination
0 0 0 0 • Imipenem, Morganella sp., Currently recommended breakpoints for imipenem have
significantly reduced susceptibility rates for imipenem compared to other carbapenems. The
0 0 0 0 clinical significance of this is not known but in absence of clinical data of efficacy use of another
carbapenem should be considered for infections caused by this organism.
0 0 0 0 • Imipenem, P. mirabilis, Currently recommended breakpoints for imipenem have significantly
reduced susceptibility rates for imipenem compared to other carbapenems. The clinical
0 0 0 0 significance of this is not known but in absence of clinical data of efficacy use of another
carbapenem should be considered for infections caused by this organism.
+ 0 0 0 • Imipenem, P. vulgaris, Currently recommended breakpoints for imipenem have significantly
reduced susceptibility rates for imipenem compared to other carbapenems. The clinical
0 0 0 0 significance of this is not known but in absence of clinical data of efficacy use of another
carbapenem should be considered for infections caused by this organism.
0 0 0 0 • Imipenem, Providencia sp., Currently recommended breakpoints for imipenem have
significantly reduced susceptibility rates for imipenem compared to other carbapenems. The
0 0 0 0 clinical significance of this is not known but in absence of clinical data of efficacy use of another
0 0 0 0 carbapenem should be considered for infections caused by this organism.
• Levofloxacin, Ehrlichia, Anaplas, Levo active in vitro in one small study
0 0 0 0 • Moxifloxacin, M. genitalium, resistance reported and emerging to all antibiotics including
fluoroquinolone
0 0 0 0 • Prulifloxacin, E. faecalis (S) , Most strains +/-, can be used in UTI, not in systemic infection.
• Rif (comb), Bartonella sp., In combination with doxycycline
0 0 0 0 • Rif (comb), Brucella sp., In combination
• Rif (comb), C. burnetii, In combination
0 0 0 0 • Rif (comb), Chlamydophila sp., In combination
• Rif (comb), E. faecalis (S) , In combination.
0 0 0 0 • Rif (comb), E. faecalis (VRE), In combination
• Rif (comb), E. faecium (S), In combination.
0 0 0 0 • Rif (comb), E. faecium (VRE), In combination
• Rif (comb), Ehrlichia, Anaplas, In combination
0 0 0 0 • Rif (comb), Legionella sp., In combination
• Rif (comb), S. aureus CA-MRSA, In combination
0 0 0 0 • Rif (comb), S. aureus HA-MRSA, In combination
• Rif (comb), S. aureus MSSA, In combination
0 0 0 0 • Rif (comb), S. lugdunensis, In combination
• Rif (comb), Staph coag-neg (R), In combination
0 0 0 0 • Rif (comb), Staph coag-neg (S), In combination
• Tetracycline, T. pallidum, Not recommended as first line therapy, but a possible alternative in
the penicillin-allergic patient
• Tetracycline, V. parahemolyticus, Resistance rates vary markedly geographically and exceed
0 0 0 0 20% in some countries.
0 0 0 0 • Tetracycline, V. vulnificus, Resistance rates vary markedly geographically and exceed 20% in
some countries.
+/- +/- 0 0 • Tigecycline, A. baumanii, Use only if no other treatment option. Use in combination
• Tigecycline, C. freundii, FDA recommends use only if no other option
• Tigecycline, C. jeikeium, Do not use unless no other option
• Tigecycline, C. koseri, FDA recommends use only if no other option
• Tigecycline, E. aerogenes, FDA suggests avoidance unless no other treatment option
• Tigecycline, E. cloacae, FDA recommends use only if no other option
• Tigecycline, E. coli (S), Use only if no other treatment option
• Tigecycline, E. coli, Klebs ESBL, Use only if no other options
• Tigecycline, E. coli, Klebs KPC, Use only if no other option
 the penicillin-allergic patient
• Tetracycline, V. parahemolyticus, Resistance rates vary markedly geographically and exceed
20% in some countries.
• Tetracycline, V. vulnificus, Resistance rates vary markedly geographically and exceed 20% in
some countries.
• Tigecycline, A. baumanii, Use only if no other treatment option. Use in combination
• Tigecycline, C. freundii, FDA recommends use only if no other option
0 0 0 0 • Tigecycline, C. jeikeium, Do not use unless no other option
• Tigecycline, C. koseri, FDA recommends use only if no other option
• Tigecycline, E. aerogenes, FDA suggests avoidance unless no other treatment option
• Tigecycline, E. cloacae, FDA recommends use only if no other option
0 0 0 0 • Tigecycline, E. coli (S), Use only if no other treatment option
• Tigecycline, E. coli, Klebs ESBL, Use only if no other options
0 0 0 0 • Tigecycline, E. coli, Klebs KPC, Use only if no other option
• Tigecycline, Enterics CRE, NOS, Use only if no other option
0 0 0 0 • Tigecycline, K. pneumoniae (S), Use only if no other option
• Tigecycline, Morganella sp., Use only if no other option
0 0 0 0 • Tigecycline, S. maltophilia, Do not use unless no other treatment options
• Tigecycline, Salmonella sp., Use only if no other treatment option
0 0 0 0 • Tigecycline, Serratia sp., Use only if no other treatment option
• Tigecycline, Shigella sp., Use only if no other treatment option

0 0 ++ 0
0 0 ++ 0
0 0 ++ 0

0 0 0 +
0 0 ++ 0
0 0 + +
0 0 0 0
+ 0 +/- ?
 Adenovirus

BK Virus

s
Cytomegaloviru
Hepatitis B

Hepatitis C

Herpes simplex

HPV

Influenza A

Influenza B

JC Virus / PML

RSV

Varicella-zoster
Viruses

Hepatitis B
Adefovir NA NA NA ++ NA NA NA NA NA NA NA NA
Emtricitabine NA NA NA +/-* NA NA NA NA NA NA NA NA
Entecavir NA NA NA ++ NA NA NA NA NA NA NA NA
Lamivudine NA NA NA +/-* NA NA NA NA NA NA NA NA
Telbivudine NA NA NA +/-* NA NA NA NA NA NA NA NA
Tenofovir NA NA NA ++ NA +/-* NA NA NA NA NA NA
Hepatitis C
Daclatasvir NA NA NA NA ++ NA NA NA NA NA NA NA
Dasabuvir NA NA NA NA ++ NA NA NA NA NA NA NA
Elbasir NA NA NA NA ++ NA NA NA NA NA NA NA
Grazoprevir NA NA NA NA ++ NA NA NA NA NA NA NA
Interferon alfa, peg NA NA NA ++ +* NA NA NA NA NA NA NA
Ledipasvir NA NA NA NA ++ NA NA NA NA NA NA NA
Ombitasvir NA NA NA NA ++ NA NA NA NA NA NA NA
Paritaprevir NA NA NA NA ++ NA NA NA NA NA NA NA
Ribavirin +/- NA NA 0 +* NA NA NA NA NA +/-* NA
Simeprevir NA NA NA NA +* NA NA NA NA NA NA NA
Sofosbuvir NA NA NA NA ++ NA NA NA NA NA NA NA
Velpatasvir NA NA NA NA ++ NA NA NA NA NA NA NA
Voxilaprevir NA NA NA NA ++ NA NA NA NA NA NA NA
Influenza
Amantadine NA NA NA NA NA NA NA +/-* +/-* NA NA NA
Oseltamivir NA NA NA NA NA NA NA ++ NA + NA NA
Peramivir NA NA NA NA NA NA NA + * + * NA NA NA
Rimantadine NA NA NA NA NA NA NA +/-* +/-* NA NA NA
Zanamavir NA NA NA NA NA NA NA ++ + NA NA NA
Herpes, CMV, VZV, misc.
Acyclovir NA NA 0 NA NA ++ NA NA NA NA NA +
Cidofovir + + ++ NA NA + * NA NA NA + * NA +
Famciclovir NA NA 0 NA NA ++ NA NA NA NA NA +
Foscarnet NA NA ++ NA NA + NA NA NA NA NA +
Ganciclovir +/- NA ++ NA NA + NA NA NA NA NA +
Letermovir NA NA ++ NA NA NA NA NA NA NA NA NA
Valacyclovir NA NA 0* NA NA ++ NA NA NA NA NA ++
Valganciclovir +/- NA ++ NA NA + NA NA NA NA NA +
Topical Agents
Imiquimod NA NA NA NA NA NA ++ NA NA NA NA NA
Penciclovir NA NA 0 NA NA + * NA NA NA NA NA 0
Podofilox NA NA NA NA NA NA ++ NA NA NA NA NA
Sinecatechins NA NA NA NA NA NA +NA NA NA NA NA
Trifluridine NA NA NA NA NA + * NA NA NA NA NA NA

Antiviral Notes:
• Hepatitis B , Emtricitabine, Do not use as mono therapy. High level resistance occurs when
emtricitabine is used alone
• Hepatitis B , Lamivudine, Do not use as mono therapy. High level resistance occurs when
lamivudine is used alone against HBV
• Hepatitis B , Telbivudine, Do not use as mono therapy. High level resistance occurs when
telbivudine is used alone
• Herpes simplex , Tenofovir, Some evidence of activity against HSV
• Hepatitis C , Interferon alfa, peg, No longer 1st line therapy
• Hepatitis C , Ribavirin, No longer 1st line therapy
• Hepatitis C , Simeprevir, No longer preferred first line therapy except in special circumstances
• RSV , Ribavirin, Minimal Activity. Palivizumab is an option for prophylaxis in
immunocompromised patients
• Influenza A , Amantadine, High level resistance H1N1 (non-swine) in 2008; Swine H1N1
susceptible
• Influenza B , Amantadine, Influenza B is intrinsically resistant
• Influenza A , Peramivir, Good option for ICU patients who cannot absorb oral agents
• Influenza B , Peramivir, Good option for ICU patients who cannot absorb oral agents
• Influenza A , Rimantadine, High level resistance H1N1 (non-swine) in 2008; Swine H1N1
susceptible
• Influenza B , Rimantadine, Influenza B is intrinsically resistant
• Herpes simplex , Cidofovir, Best option when ACV resistance is present
• JC Virus / PML , Cidofovir, Data support its use is inconclusive. When used properly, with
appropriate pre- medication with probenecid and fluids, appears to work well vs. JC virus CNS
disease
• Cytomegalovirus , Letermovir, CMV prophylaxis in transplant pts
• Herpes simplex , Penciclovir, Topical use only
• Herpes simplex , Trifluridine, For ophthalmic use

Recommended (+
+) active in vitro, clinically effective, guideline
Agent is a first line therapy: reliably
recommended, recommended as a first-line agent or acceptable alternative agent
in the Sanford Guide.
Active (+)
Agent is a potential alternative agent (active in vitro, possesses class activity
comparable to known effective agents or a therapeutically interchangeable
agents and hence likely to be clinically effective, but second line due to overly
broad spectrum, toxicity, limited clinical experience, or paucity of direct
evidence of
effectiveness).
Variable
Variable activity such that the agent, (+/-)
although clinically effective in some settings
or types of infections is not reliably effective in others, or should be used in
combination with another agent, and/or its efficacy is limited by resistance which
has been
associated with treatment failure.
Not Recommended
(0)
Agent is a poor alternative to other agents because resistance to likely to be
present
or occur, due to poor drug penetration to site of infection or an unfavorable toxicity
profile, or limited or anecdotal clinical data to support effectiveness.

Insufficient Data (?)

Insufficient data to recommend
use. Not Applicable (NA)
Agent has no activity against this
pathogen.
Editorial Note: The data provided are intended to serve as a general guide to antibacterial usefulness based on treatment guidelines and
recommendations, in vitro activity, predominant patterns of susceptibility or resistance and/or demonstrated clinical effectiveness. Variability in
resistance patterns due to regional differences or as a consequent of clinical setting (e.g., community-onset vs. ICU-acquired infection) should be taken
into account when using this table because activities of certain agents can differ significantly from what is shown in the table, which are by necessity
based on aggregate information.

Cairo University Specialized Pediatric Hospital, Medication Consultation Unit, Clinical Pharmacy D